Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 217269, 7 pages
http://dx.doi.org/10.1155/2014/217269
Research Article

Hyperammonemia Associated with Valproic Acid Concentrations

1Pharmaceutical Sciences Department, Faculty of Chemistry, Universidad de la República, Avenida General Flores 2124, P.O. Box 1157, 11800 Montevideo, Uruguay
2Therapeutic Drug Monitoring Service, “Dr. Manuel Quintela” Clinical Hospital, Universidad de la República, Avenida Italia s/n, 11609 Montevideo, Uruguay
3“Sanatorio Canzani” Hospital, Banco de Previsión Social, Martín García 1363, 11800 Montevideo, Uruguay

Received 10 February 2014; Revised 28 March 2014; Accepted 11 April 2014; Published 29 April 2014

Academic Editor: Slaven Erceg

Copyright © 2014 Marta Vázquez et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Meibohm, I. Beierle, and H. Derendorf, “How important are gender differences in pharmacokinetics?” Clinical Pharmacokinetics, vol. 41, no. 5, pp. 329–342, 2002. View at Google Scholar · View at Scopus
  2. A. A. Mangoni and S. H. D. Jackson, “Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications,” British Journal of Clinical Pharmacology, vol. 57, no. 1, pp. 6–14, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Quteineh, C. Verstuyft, V. Furlan et al., “Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients,” Basic & Clinical Pharmacology & Toxicology, vol. 103, no. 6, pp. 546–552, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Vázquez, P. Fagiolino, C. Maldonado, M. Ibarra, and A. Boronat, “Impact of severe sepsis or septic shock on drug response,” in Severe Sepsis and Septic Shock—Understanding a Serious Killer, R. Fernandez, Ed., pp. 187–200, InTech, 2012. View at Publisher · View at Google Scholar
  5. M. Vázquez, P. Fagiolino, and C. Maldonado, “Relationship between serum creatinine and tacrolimus clearance in renal transplant patients,” Latin American Journal of Pharmacy, vol. 32, no. 9, pp. 1422–1425, 2013. View at Google Scholar
  6. M. Vázquez, P. Fagiolino, A. Boronat, M. Buroni, and C. Maldonado, “Therapeutic drug monitoring of vancomycin in severe sepsis and septic shock,” International Journal of Clinical Pharmacology and Therapeutics, vol. 46, no. 3, pp. 140–145, 2008. View at Google Scholar · View at Scopus
  7. W. Loscher, “Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action,” Progress in Neurobiology, vol. 58, no. 1, pp. 31–59, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Ghodke-Puranik, C. F. Thorn, J. K. Lamba et al., “Valproic acid pathway: pharmacokinetics and pharmacodynamics,” Pharmacogenetics and Genomics, vol. 23, no. 4, pp. 236–241, 2013. View at Publisher · View at Google Scholar
  9. P. M. Haddad, A. Das, M. Ashfaq, and A. Wieck, “A review of valproate in psychiatric practice,” Expert Opinion on Drug Metabolism & Toxicology, vol. 5, no. 5, pp. 539–551, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Wadzinski, R. Franks, D. Roane, and M. Bayard, “Valproate-associated hyperammonemic encephalopathy,” The Journal of the American Board of Family Medicine, vol. 20, no. 5, pp. 499–502, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Siemes, H. Nau, K. Schultze et al., “Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity,” Epilepsia, vol. 34, no. 2, pp. 332–346, 1993. View at Google Scholar · View at Scopus
  12. Y. Ohtani, F. Endo, and I. Matsuda, “Carnitine deficiency and hyperammonemia associated with valproic acid therapy,” The Journal of Pediatrics, vol. 101, no. 5, pp. 782–785, 1982. View at Google Scholar · View at Scopus
  13. M. M. Mehndiratta, P. Mehndiratta, P. Phul, and S. Garg, “Valproate induced non hepatic hyperammonaemic encephalopathy (VNHE)—a study from tertiary care referral university hospital, North India,” The Journal of the Pakistan Medical Association, vol. 58, no. 11, pp. 627–631, 2008. View at Google Scholar · View at Scopus
  14. E. E. Benarroch, “Neuron-astrocyte interactions: partnership for normal function and disease in the central nervous system,” Mayo Clinic Proceedings, vol. 80, no. 10, pp. 1326–1338, 2005. View at Google Scholar · View at Scopus
  15. A. Lemberg and A. Fernández, “Hepatic encephalopathy, ammonia, glutamate, glutamine and oxidative stress,” Annals of Hepatology, vol. 8, no. 2, pp. 95–102, 2009. View at Google Scholar · View at Scopus
  16. M. Vázquez, S. Fernández, A. Scaramelli, P. Fagiolino, and A. Laborde, “Interdisciplinariedad desde la práctica. Encefalopatía asociada a ácido valproico. Reporte de un caso,” in En Clave Inter 2010. Reflexiones Sobre la Interdisciplina en la Universidad de la República, vol. 1, pp. 1–5, Espacio Interdisciplinario de la Universidad de la República, 2010. View at Google Scholar
  17. M. Vázquez, P. Fagiolino, and E. L. Mariño, “Concentration-dependent mechanisms of adverse drug reactions in epilepsy,” Current Pharmaceutical Design, vol. 19, no. 38, pp. 6802–6808, 2013. View at Publisher · View at Google Scholar
  18. T. Gerstner, D. Buesing, E. Longin et al., “Valproic acid induced encephalopathy—19 new cases in Germany from 1994 to 2003—a side effect associated to VPA-therapy not only in young children,” Seizure, vol. 15, no. 6, pp. 443–448, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. D. L. Coulter and R. J. Allen, “Hyperammonemia with valproic acid therapy,” The Journal of Pediatrics, vol. 99, no. 2, pp. 317–319, 1981. View at Google Scholar · View at Scopus
  20. R. B. Carr and K. Shrewsbury, “Hyperammonemia due to valproic acid in the psychiatric setting,” The American Journal of Psychiatry, vol. 164, no. 7, pp. 1020–1027, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. D. L. Coulter and R. J. Allen, “Secondary hyperammonaemia: a possible mechanism for valproate encephalophathy,” The Lancet, vol. 1, no. 8181, pp. 1310–1311, 1980. View at Google Scholar · View at Scopus
  22. N. Segura-Bruna, A. Rodriguez-Campello, V. Puente, and J. Roquer, “Valproate-induced hyperammonemic encephalopathy,” Acta Neurologica Scandinavica, vol. 114, no. 1, pp. 1–7, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Hoppel, “The role of carnitine in normal and altered fatty acid metabolism,” American Journal of Kidney Diseases, vol. 41, supplement 4, pp. S4–S12, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Maldonado, P. Fagiolino, M. Vázquez et al., “Therapeutic carbamazepine (CBZ) and valproic acid (VPA) monitoring in children using saliva as a biologic fluid,” Journal of Epilepsy and Clinical Neurophysiology, vol. 14, no. 2, pp. 55–58, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Ibarra, M. Vázquez, P. Fagiolino, F. Mutilva, and A. Canale, “Total, unbound plasma and salivary phenytoin levels in critically ill patients,” Journal of Epilepsy and Clinical Neurophysiology, vol. 16, no. 2, pp. 69–73, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Fagiolino, M. Vázquez, C. Maldonado et al., “Usefulness of salivary drug monitoring for detecting efflux transporter overexpression,” Current Pharmaceutical Design, vol. 19, no. 38, pp. 6767–6774, 2013. View at Google Scholar
  27. P. N. Patsalos and D. J. Berry, “Therapeutic drug monitoring of antiepileptic drugs by use of saliva,” Therapeutic Drug Monitoring, vol. 35, no. 1, pp. 4–29, 2013. View at Publisher · View at Google Scholar
  28. F. Monaco, S. Piredda, R. Mutani, C. Mastropaolo, and M. Tondi, “The free fraction of valproic acid in tears, saliva, and cerebrospinal fluid,” Epilepsia, vol. 23, no. 1, pp. 23–26, 1982. View at Google Scholar · View at Scopus
  29. H. Amini, M. Javan, and A. Ahmadiani, “Development and validation of a sensitive assay of valproic acid in human plasma by high-performance liquid chromatography without prior derivatization,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 830, no. 2, pp. 368–371, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Uematsu, M. Yamaoka, R. Doto, H. Tanaka, T. Matsuura, and K. Furusawa, “Expression of ATP-binding cassette transporter in human salivary ducts,” Archives of Oral Biology, vol. 48, no. 1, pp. 87–90, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Baltes, M. Fedrowitz, C. L. Tortós, H. Potschka, and W. Löscher, “Valproic acid is not a substrate for P-glycoprotein or multidrug resistance proteins 1 and 2 in a number of in vitro and in vivo transport assays,” The Journal of Pharmacology and Experimental Therapeutics, vol. 320, no. 1, pp. 331–343, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Dutta, Y. Zhang, D. S. Selness, L. L. Lee, L. A. Williams, and K. W. Sommerville, “Comparison of the bioavailability of unequal doses of divalproex sodium extended-release formulation relative to the delayed-release formulation in healthy volunteers,” Epilepsy Research, vol. 49, no. 1, pp. 1–10, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. D. C. de Vivo, T. P. Bohan, D. L. Coulter et al., “l-carnitine supplementation in childhood epilepsy: current perspectives,” Epilepsia, vol. 39, no. 11, pp. 1216–1225, 1998. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Perrott, N. G. Murphy, and P. J. Zed, “l-carnitine for acute valproic acid overdose: a systematic review of published cases,” The Annals of Pharmacotherapy, vol. 44, no. 7-8, pp. 1287–1293, 2010. View at Google Scholar · View at Scopus
  35. T. P. Bohan, E. Helton, I. Mc Donald et al., “Effect of l-carnitine treatment for valproate-induced hepatotoxicity,” Neurology, vol. 56, no. 10, pp. 1405–1409, 2001. View at Google Scholar · View at Scopus
  36. D. S. Millington, T. P. Bohan, C. R. Roe, A. L. Yergey, and D. J. Liberato, “Valproylcarnitine: a novel drug metabolite identified by fast atom bombardment and thermospray liquid chromatography-mass spectrometry,” Clinica Chimica Acta, vol. 145, no. 1, pp. 69–76, 1985. View at Publisher · View at Google Scholar · View at Scopus
  37. P. E. R. Lheureux, A. Penaloza, S. Zahir, and M. Gris, “Science review: carnitine in the treatment of valproic acid-induced toxicity—what is the evidence?” Critical Care, vol. 9, no. 5, pp. 431–440, 2005. View at Publisher · View at Google Scholar · View at Scopus